Follow the research roles, not just the funding label

The funding line is one of the first things many readers check in a peptide paper. It should be read, but it should not end the appraisal. Industry funding does not automatically make a finding false, and a noncommercial institution does not make a study immune to bias. The more useful question is what the people and organisations involved were able to influence: the research question, the protocol, the analysis, access to the data and the decision to publish.

Transparency makes these roles visible enough to examine. A disclosure statement, sponsor-role paragraph, trial registry and protocol provide different pieces of that picture. An investigator may have a financial relationship while the paper still reports a carefully specified study; another paper may offer little information about who controlled the analysis. These situations call for examination of the evidence and its reporting rather than a shortcut based on the sponsor's name.

This November 2026 editorial sets out a practical way to follow that chain. It also applies the same standard to research summaries: readers should know which sources support a factual claim, where commercial relationships may be relevant and whether an editorial has received independent clinical review. A polished explanation is not proof of independence. The goal is an auditable account of how a conclusion was reached, with limitations stated clearly enough that another reader can challenge it. The practical test is whether the source trail remains inspectable.